Latest News Archive

Please select Category, Year, and then Month to display items

‘Wokeness’ could threaten our constitutional democracy, says Helen Zille

02 August 2021 | Story Sanet Madonsela | Photo Supplied

iStock-1249723002 copy — Helen Zille unpacking the notion of ‘wokeness’ and its context within the broader South Africa during a virtual book discussion with Prof Hussein Solomon.

The Department of Political Studies and Governance at the University of the Free State hosted Helen Zille, Chairperson of the Federal Council of the Democratic Alliance, to discuss her book #StayWoke: Go Broke: Why South Africa won’t survive America’s culture wars (and what you can do about it). Zille was in discussion with the Academic Head of Department, Prof Hussein Solomon. She unpacked the notion of ‘wokeness’ – also known as the ‘critical theory’, as well as the emergence of a ‘cancel culture’ in broader society.

Zille explained how the woke ideology combines post-modernism and neo-Marxism and why intersectionality often features in the lexicons (vocabulary) of South African universities.

Wokeness and its threat to our Constitution

Zille explained that wokeness threatens South Africa’s constitutional democracy. “Unlike America, South Africa’s democratic institutions are fragile and new and may not be able to survive the wave of wokeness,” she said. She further explained how the ‘properly wokes’ request to have separate graduations for African students could not work and how South Africa’s Constitution promotes inclusion.

Zille believes that the country needs its young people to be critical thinkers, as this can assist in stabilising the country’s economy and internal challenges. She believes that society needs a range of paradigms to make sense of the world, processes, programmes, and history and that it should not be overly reliant on a singular view, as this could have negative implications on the country in the long term. Zille concluded that she remains hopeful for the country, as its citizens are intelligent, sensible, ethical, and rational enough to move it forward and assist in reaching its full potential.

Wokeness aims to overthrow societal hierarchy

Zille notes in her book that 'wokeness is an attempt to invert ‘society’s conventional hierarchy of privilege in order to promote marginalised identities.' This stems from a struggle against inborn attributes of personal identity such as race, sex, sexuality, gender, and disability. It believes that society comprises power hierarchies that determine what should be known and what shouldn’t, as well as how events and actions should be interpreted. It believes that social justice activists need to expose unequal power relations and dismantle them in order to achieve social justice.

Unequal power relations in this regard include racism, sexism, homophobia, transphobia, fatphobia, and other prejudices. Moreover, it argues that knowledge needs to be decolonised in order to achieve social justice. Decolonisation would require stripping knowledge of the methods and contents used in Western society. While it ‘seeks’ to promote inclusion, wokeness has begun to symbolise an extreme intolerance and is often used as a tool to enable a cancel culture. As a movement, it has been used to tear down statues, deface paintings, and monitor others’ speech infringements to ensure conformity. Rather than engage in rational debates with those who share dissenting views, online woke communities silence people with opposing views. This threatens social progress. Zille’s book represents a valuable contribution and a necessary attempt to understand the phenomenon and why it would not work in the South African context.

Having personally experienced the wave of wokeness and cancel culture, Zille is well placed to advise others experiencing such tactics. She advises them to recognise what happened and to remain calm; to question whether they said or did anything objectionable or whether they just undermined the woke narrative; not to apologise or resign, as it feeds into the narrative that they have done something wrong; to seek legal counsel if they can afford it; not to engage online mobs; and not to give up.

Watch recording of webinar below:

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept